Raymond James Financial’s AbCellera Biologics ABCL Stock Holding History
Bought
Maintained
Sold
Other funds holding ABCL
BBA
Raymond James Financial's ABCL Position: Q3 2026 in Review
Raymond James Financial reduced its AbCellera Biologics (ABCL) stake by 10% in Q3 2026, selling an estimated $31.7K and leaving 29,856 shares worth $436K. The position accounts for ﹤0.01% of the portfolio, ranked #4657.
Raymond James Financial first reported a position in ABCL in Q4 2024 and has held it in 8 quarters since. The position peaked at $1.01M in Q1 2026. 163 funds tracked by Wall St. Rank hold ABCL as of Q3 2026.
- Raymond James Financial held 29,856 shares of AbCellera Biologics worth $436K as of Q3 2026.
- Raymond James Financial sold 3,344 AbCellera Biologics shares in Q3 2026, an estimated $31.7K.
- AbCellera Biologics made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #4657 holding.
- Raymond James Financial first reported a position in AbCellera Biologics in Q4 2024 and has held it in 8 quarters since.
- Raymond James Financial's AbCellera Biologics position peaked at $1.01M in Q1 2026.
- 163 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2026.
Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.